Remove DNA Remove Gene Sequencing Remove Medicine
article thumbnail

Hopkins-led research team takes gene mutation detection in blood to the next level

Scienmag

Credit: Elizabeth Cooke Next-generation gene sequencing (NGS) technologies –in which millions of DNA molecules are simultaneously but individually analyzed– theoretically provides researchers and clinicians the ability to noninvasively identify mutations in the blood stream.

article thumbnail

Takeda grows in gene therapies again with $2bn Code Bio deal

pharmaphorum

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The deal is mostly back-loaded, with “double-digit million” dollars in upfront payment, research funding and milestone payments.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Next Generation Sequencing (NGS) Library Preparation Kits Market: Current Scenario and Future Potential

Roots Analysis

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

article thumbnail

UK cancer mutation testing firm Biofidelity raises $12m

pharmaphorum

Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing. Both previously worked at Cambridge-based DNA sequencing specialist Base4 Innovation, where the technology was developed.

DNA 59
article thumbnail

Touchlight boosts DNA manufacturing capacity with latest expansion

Pharmaceutical Technology

Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.

DNA 130
article thumbnail

A Reversal on Sequencing? Proposed Legislation Would Allow Patenting of Naturally Occurring Genes

FDA Law Blog

Rather, developers of diagnostic tests and, indeed of any product that relies on free access to gene sequence and other biomarker information, should pay also close attention, as PERA would overturn longstanding judicial precedent. animal, viral, bacterial) DNA and RNA sequences. Supporters of AMP v.

Gene 64